tiprankstipranks
Trending News
More News >

BeOne Medicines Ltd. Announces Post-Effective Amendment to Form S-3

Story Highlights
BeOne Medicines Ltd. Announces Post-Effective Amendment to Form S-3

Confident Investing Starts Here:

BeiGene Ltd ( (HK:6160) ) has provided an announcement.

BeOne Medicines Ltd., a Switzerland-based company, has announced a post-effective amendment to its Form S-3 registration statement filed with the U.S. Securities and Exchange Commission. This move allows the company to offer securities on a delayed or continuous basis under Rule 415 of the Securities Act of 1933, potentially enhancing its financial flexibility and market presence.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

More about BeiGene Ltd

Average Trading Volume: 6,789,106

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$236.3B

Learn more about 6160 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App